Merck Sharp & Dohme LLC: Clinical Trials

2730 completed, 523 terminated, 309 active not recruiting, 295 recruiting. 1405 Phase 2, 1153 Phase 1, 925 Phase 3, 392 Phase 4, 211 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	1405	Completed 692, Terminated 239, Active not recruiting 168, Recruiting 166, Unknown 55, Withdrawn 54, Not yet recruiting 28, Suspended 3
Phase 1	1153	Completed 781, Terminated 157, Recruiting 87, Active not recruiting 75, Withdrawn 23, Unknown 19, Not yet recruiting 10, Suspended 1
Phase 3	925	Completed 641, Terminated 96, Active not recruiting 81, Recruiting 65, Withdrawn 24, Unknown 13, Not yet recruiting 4, Suspended 1
Phase 4	392	Completed 263, Terminated 50, Unknown 36, Withdrawn 25, Recruiting 7, Active not recruiting 6, Not yet recruiting 5
Not applicable	211	Completed 146, Unknown 25, Terminated 13, Recruiting 12, Withdrawn 10, Active not recruiting 2, Not yet recruiting 2, Enrolling by invitation 1
Early Phase 1	28	Completed 16, Terminated 4, Active not recruiting 3, Unknown 3, Recruiting 1, Withdrawn 1

Follow Merck Sharp & Dohme LLC: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Coronary Artery Calcium (CAC) Testing in Primary Care Our Practice Advisory (OPA) - ASCVD, ASCVD Management	Not applicable	Not yet recruiting	Weill Medical College of Cornell University	20	2027-02-01	2026-10-15
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) Ulonivirine - Hepatic Insufficiency	Phase 1	Not yet recruiting	Merck Sharp & Dohme LLC	22	2027-01-22	2026-07-16
A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) MK-7602, Pyronaridine - Healthy	Phase 1	Not yet recruiting	Merck Sharp & Dohme LLC	24	2027-01-04	2026-11-05
Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer Sacituzumab Tirumotecan - Penile Squamous Cell Carcinoma, Metastatic Penile Squamous Cell Carcinoma	Phase 2	Not yet recruiting	Latin American Cooperative Oncology Group	37	2027-01-01	2026-09-11
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory	Phase 2	Not yet recruiting	Olivia Newton-John Cancer Research Institute	25	2027-01-01	2026-11-03
DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg DOR/ISL - HIV-1, HIV Infection	Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	45	2026-12-23	2026-10-07
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer	Phase 1 / Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	290	2026-12-14	2026-11-02
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma	Phase 2 / Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	470	2026-12-13	2026-11-05
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) MK-6916 - Healthy, Renal Impairment	Phase 1	Not yet recruiting	Merck Sharp & Dohme LLC	32	2026-12-11	2026-11-06
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) Gocatamig, Durvalumab, Rescue Medications - Small Cell Lung Cancer	Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	564	2026-12-07	2026-11-02
Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) Pembroluzimab, Observation - HPV-positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma	Phase 2	Withdrawn	Dana-Farber Cancer Institute		2026-12-01	2026-10-08
Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis* GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) - Recurrent Respiratory Papillomatosis (RRP)	Phase 1 / Phase 2	Not yet recruiting	Ohio State University	50	2026-12-01	2026-10-22
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2	Recruiting	Fred Hutchinson Cancer Center	20	2026-12-01	2026-10-29
Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial Best Practice, Educational Intervention, Interview - Human Papillomavirus-Related Carcinoma	Not applicable	Recruiting	Fred Hutchinson Cancer Center	1900	2026-12-01	2026-10-29
A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) Midazolam, Rosuvastatin, MK-6916 - Healthy	Phase 1	Not yet recruiting	Merck Sharp & Dohme LLC	18	2026-11-30	2026-10-07
CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma	Phase 1 / Phase 2	Suspended	Mayo Clinic	23	2026-11-30	2026-10-20
A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension (MK-7962-022) Sotatercept - Hypertension, Pulmonary	Phase 4	Not yet recruiting	Merck Sharp & Dohme LLC	40	2026-11-30	2026-10-28
A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041) Sotatercept, Placebo - Pulmonary Hypertension	Phase 3	Not yet recruiting	Merck Sharp & Dohme LLC	352	2026-11-26	2026-10-23
A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) MK-8690, Placebo, Methotrexate (MTX) - Rheumatoid Arthritis	Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	60	2026-11-23	2026-10-26
A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007) MK-6916, Hydrocodone/acetaminophen (HB/APAP), MK-6916 Placebo - Pain Management	Phase 2	Not yet recruiting	Merck Sharp & Dohme LLC	380	2026-11-23	2026-11-06

Showing 20 of 4275. Sign in to see all of them.

Conditions studied

Diabetes Mellitus, Type 2 (227)  ·  Carcinoma, Non-Small-Cell Lung (218)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (192)  ·  HIV Infections (163)  ·  Neoplasms (152)  ·  Hepatitis C (141)  ·  Melanoma (131)  ·  Hepatitis C, Chronic (126)  ·  Breast Neoplasms (124)  ·  Acquired Immunodeficiency Syndrome (86)  ·  Colorectal Neoplasms (85)  ·  Ovarian Neoplasms (83)  ·  Neoplasm Metastasis (82)  ·  Squamous Cell Carcinoma of Head and Neck (77)  ·  Uterine Cervical Neoplasms (75)

Interventions

pembrolizumab (1051)  ·  Carboplatin (148)  ·  Cisplatin (127)  ·  Paclitaxel (127)  ·  Sitagliptin Phosphate (125)  ·  peginterferon alfa-2b (116)  ·  Ribavirin (112)  ·  Raltegravir Potassium (109)  ·  lenvatinib (101)  ·  Vorinostat (94)  ·  Metformin (81)  ·  Sugammadex (72)  ·  Pemetrexed (68)  ·  Gemcitabine (66)  ·  Aprepitant (59)

Countries

United States (1812)  ·  Spain (453)  ·  France (400)  ·  Canada (387)  ·  United Kingdom (377)  ·  Germany (356)  ·  Australia (354)  ·  Italy (348)  ·  South Korea (334)  ·  Japan (300)  ·  Israel (262)  ·  Poland (256)  ·  Taiwan (237)  ·  China (227)  ·  Netherlands (206)

Top investigators

Amy Schaberg, BSN (12)  ·  Mark Jones, MD (6)  ·  Reza Haque, MD, PhD (6)  ·  Gregory D Zimet, PhD (5)  ·  Reza Haque, MD (5)

Results publications

PMID 31395089, PMID 34213819, PMID 35101941, PMID 41276263, PMID 29461687, PMID 33813736, PMID 27422279, PMID 28193518, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 29404492, PMID 33300372, PMID 37699333, PMID 19935017, PMID 32184277, PMID 32305010, PMID 37465924, PMID 21401833, PMID 22500948, PMID 28647166, PMID 32700393, PMID 32926419, PMID 38642841, PMID 41166720, PMID 12795371, PMID 19236277, PMID 19236279, PMID 25633134, PMID 26947564, PMID 27072496, PMID 27807285, PMID 28265715, PMID 28427826, PMID 29074187, PMID 29211620, PMID 30117761, PMID 30202085, PMID 30736858, PMID 30982556, PMID 31064361, PMID 31121013, PMID 31982148, PMID 33360855, PMID 33792646, PMID 34754076, PMID 35421228, PMID 36529106

NIH funding

2023 (135), 2018 (69), 2017 (58), 2019 (56), 2014 (55), 2015 (55), 2016 (44), 2025 (41), 2009 (28), 2008 (18), 2005 (11), P30CA060553 (8), P30CA138292 (8), 2004 (5), P30CA093373 (2)